Duality Advisers LP Takes $715,000 Position in Becton, Dickinson and Company (NYSE:BDX)

Duality Advisers LP bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,932 shares of the medical instruments supplier’s stock, valued at approximately $715,000.

A number of other large investors have also recently modified their holdings of BDX. Ontario Teachers Pension Plan Board boosted its stake in Becton, Dickinson and Company by 242.8% during the third quarter. Ontario Teachers Pension Plan Board now owns 1,783,769 shares of the medical instruments supplier’s stock worth $461,158,000 after acquiring an additional 1,263,391 shares in the last quarter. Vanguard Group Inc. boosted its stake in Becton, Dickinson and Company by 2.0% during the third quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock worth $6,703,041,000 after acquiring an additional 516,427 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Becton, Dickinson and Company by 11.0% during the third quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock worth $1,342,503,000 after acquiring an additional 512,566 shares in the last quarter. Royal Bank of Canada boosted its stake in Becton, Dickinson and Company by 28.5% during the third quarter. Royal Bank of Canada now owns 2,139,493 shares of the medical instruments supplier’s stock worth $553,121,000 after acquiring an additional 473,914 shares in the last quarter. Finally, Morgan Stanley boosted its stake in Becton, Dickinson and Company by 4.5% during the third quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock worth $2,637,062,000 after acquiring an additional 435,168 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the sale, the senior vice president now directly owns 2,276 shares of the company’s stock, valued at $542,348.04. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.31% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

BDX has been the topic of several research reports. Raymond James boosted their price objective on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Barclays lifted their target price on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $280.00.

Becton, Dickinson and Company Stock Down 0.3 %

BDX opened at $233.73 on Thursday. The company has a quick ratio of 0.64, a current ratio of 1.08 and a debt-to-equity ratio of 0.56. The firm has a 50 day moving average price of $239.62 and a 200-day moving average price of $241.73. Becton, Dickinson and Company has a twelve month low of $229.40 and a twelve month high of $287.32. The stock has a market capitalization of $67.52 billion, a price-to-earnings ratio of 55.39, a PEG ratio of 1.93 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.29. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.73 billion. During the same period in the previous year, the company earned $2.98 earnings per share. The firm’s quarterly revenue was up 2.6% on a year-over-year basis. Equities research analysts forecast that Becton, Dickinson and Company will post 12.94 earnings per share for the current year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.